Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bank Systems & Technology May 26, 2008 Lisa Valentine	EVP and CIO Paul Johnson Guides BB&T Corp. in Organic Growth Financial services giant BB&T is looking at organic growth to fuel its future success by transforming the firm's IT organization into a "value center" more akin to a line of business.
Bank Director 3rd Quarter 2009 John R. Engen	Capitalizing on Opportunities BB&T Corp. calls itself a "fast follower" -- a player that doesn't try to get there first with technology, but takes advantage of every smart play.
Insurance & Technology October 8, 2007	Rick Roy Draws Lessons from CUNA Mutual's Transformation Initiative The insurance company's former CIO and current SVP reflects on the lessons learned from the carrier's initiative to transform customer operations.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool October 6, 2009 Jennifer Schonberger	This Is How We Should Fix the Financial System Economist Simon Johnson says a decision about regulating derivatives was the defining event.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool December 1, 2010 Brian Orelli	We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool June 28, 2011 Brian Orelli	HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments.
CRM December 2013 Esteban Kolsky	The Digital Transformation of CRM When the world is changing, businesses must do the same.
The Motley Fool October 17, 2006 Brian Lawler	See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note.
CIO April 11, 2011 Bill Bulkeley	How Cloud Computing Rose From Lehman Brothers' Ashes The inside story of how Lehman Brothers is being dismantled in the cloud
The Motley Fool September 14, 2009 Brian Orelli	The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool August 14, 2007 Brian Orelli	A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare.
The Motley Fool May 22, 2009 Brian Orelli	J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool June 25, 2010 Brian Orelli	The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool February 22, 2010 Brian Orelli	So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits.
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
CIO Adam Dennison	CIO magazine makes the digital leap CIO is taking a huge step in its own digital transformation: The November 1, 2015, issue of CIO magazine is our final edition in print.
The Motley Fool November 28, 2008 Brian Orelli	The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value.
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.
Global Services July 1, 2008 Imrana Khan	The Case for Transformation Beyond the hype about transformation there's some real work being delivered that makes the case for business transformation outsourcing.
CIO September 12, 2011 Kathleen Carr	One CIO Shares the Secrets to Successful IT Transformation David Banks, the first CIO ever at Cumberland-Gulf, kept asserting the importance of the CIO role while accelerating the company's IT transformation.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
CIO September 23, 2010	Download Best Practices for Advancing the CIO Role Survey results help identify how CIOs are shifting their primary focus from the internal and functional to the enterprise and transformational, and ultimately to the external and business strategy.
Insurance & Technology April 20, 2005 Anthony O'Donnell	Johnson Goes Global Insurers must outsource to meet the current challenges of the industry such as regulatory scrutiny and pressure to streamline business.
The Motley Fool July 12, 2010 Brian Orelli	Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up.
The Motley Fool January 8, 2008 Mac Greer	Fool Video: The Best Stock for 2008, Buffett's Latest, and Bear Market Buys Can Apple continue to produce? Will McDonald's serve up big earnings? Is 2008 the year for Johnson & Johnson? Will Starbucks continue to yield not-so-grande returns? These and other questions are answered in this video.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool August 29, 2011 Brian Orelli	A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool July 20, 2010 Brian Orelli	Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant.
CIO December 1, 2005 Dan S. Cohen	Why Change Is an Affair of the Heart It is not the complexity of the technology, a lack of buy-in from top management, high cost or the failure to create shareholder value that derails new IT projects. Instead, the single biggest challenge in any transformation project is simply getting people to change their behavior.